Rss Feed
Tweeter button
Facebook button
Webonews button

Shire in good health after drug trial boost

Shire was boosted yesterday by promising trial data for a drug to treat a rare and sometimes deadly hereditary disease.

The FTSE 100 pharmaceuticals group, which has grown dramatically through acquisitions, was among the top performers in an otherwise downbeat blue-chip index.

Analysts have predicted that the treatment could generate more than $2 billion a year in sales.

Under Flemming Ornskov, its chief executive, Shire is focusing on treatments for rare diseases and cancer. It said yesterday that a treatment for hereditary angioedema had performed well in a late-stage trial.

Hereditary angioedema is an immune disorder that causes severe swelling. Shire’s drug, lanadelumab, prevents those attacks. Shire said that the phase 3 trial data would form the basis of a marketing application in the US.

Article source:

Speak Your Mind